butyldeoxynojirimycin + zidovudine

This is a **combination drug** consisting of butyldeoxynojirimycin (specifically, N-butyl-deoxynojirimycin, also known as SC-48334) and **zidovudine**. Butyldeoxynojirimycin is a small molecule inhibitor of alpha-glucosidase I, which interferes with the glycosylation and maturation of viral envelope glycoproteins, reducing HIV infectivity. Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks the conversion of viral RNA into DNA, further inhibiting viral replication. This combination has been studied in phase II clinical trials for HIV-1 infection in individuals with moderate CD4 counts. The main therapeutic rationale is targeting viral replication through two different mechanisms: one disrupting glycoprotein processing (butyldeoxynojirimycin) and the other inhibiting reverse transcription (zidovudine)[1][3][5].

Other names

N-butyl-deoxynojirimycin + zidovudineSC-48334 + zidovudine